Figure 6
TCDD induces hsa-miR-608 and CDC42 expression via AhR-dependent pathway. Cells were treated with 10−6 M CH223191 (AhR antagonist) or 0.01% DMSO for 3 hr before treatment with 10−10 M TCDD or 0.01% DMSO for 36 hr (A) and 24 hr (B). Total miRs/mRNA was extracted for determination of the expression level of hsa-miR-608 (A) or CDC42 (B). Quantitative PCR analyses were performed as mentioned in M & M. U6 rRNA was used as an internal control for hsa-miR-608 and 18 S rRNA was used as an internal control for CDC42. Values were expressed as mean ± S.E. (n = 3) and each independent sample was detected in triplicate. Statistical analysis was done by one-way ANOVA with Bonferroni test. *p < 0.05 and **p < 0.01compared with control (DMSO treated cells). #p < 0.05 compared with TCDD treatment alone.
